» Articles » PMID: 24962785

Anti-inflammatory and Anti-cancer Activity of Mulberry (Morus Alba L.) Root Bark

Overview
Publisher Biomed Central
Date 2014 Jun 26
PMID 24962785
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Root bark of mulberry (Morus alba L.) has been used in herbal medicine as anti-phlogistic, liver protective, kidney protective, hypotensive, diuretic, anti-cough and analgesic agent. However, the anti-cancer activity and the potential anti-cancer mechanisms of mulberry root bark have not been elucidated. We performed in vitro study to investigate whether mulberry root bark extract (MRBE) shows anti-inflammatory and anti-cancer activity.

Methods: In anti-inflammatory activity, NO was measured using the griess method. iNOS and proteins regulating NF-κB and ERK1/2 signaling were analyzed by Western blot. In anti-cancer activity, cell growth was measured by MTT assay. Cleaved PARP, ATF3 and cyclin D1 were analyzed by Western blot.

Results: In anti-inflammatory effect, MRBE blocked NO production via suppressing iNOS over-expression in LPS-stimulated RAW264.7 cells. In addition, MRBE inhibited NF-κB activation through p65 nuclear translocation via blocking IκB-α degradation and ERK1/2 activation via its hyper-phosphorylation. In anti-cancer activity, MRBE deos-dependently induced cell growth arrest and apoptosis in human colorectal cancer cells, SW480. MRBE treatment to SW480 cells activated ATF3 expression and down-regulated cyclin D1 level. We also observed that MRBE-induced ATF3 expression was dependent on ROS and GSK3β. Moreover, MRBE-induced cyclin D1 down-regulation was mediated from cyclin D1 proteasomal degradation, which was dependent on ROS.

Conclusions: These findings suggest that mulberry root bark exerts anti-inflammatory and anti-cancer activity.

Citing Articles

Widely Targeted Metabolomics Analysis to Reveal Metabolite of L. in Different Medicinal Parts.

Wang X, Qian Y, Wei M Molecules. 2024; 29(17).

PMID: 39274829 PMC: 11395776. DOI: 10.3390/molecules29173981.


Morus alba: a comprehensive phytochemical and pharmacological review.

El-Saber Batiha G, Al-Snafi A, Thuwaini M, Teibo J, Shaheen H, Akomolafe A Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(7):1399-1413.

PMID: 36877269 PMC: 10244279. DOI: 10.1007/s00210-023-02434-4.


Sericultural By-Products: The Potential for Alternative Therapy in Cancer Drug Design.

Baci G, Baciu E, Cucu A, Musca A, Giurgiu A, Moise A Molecules. 2023; 28(2).

PMID: 36677907 PMC: 9861160. DOI: 10.3390/molecules28020850.


Anti-Cancer Effects of a New Herbal Medicine PSY by Inhibiting the STAT3 Signaling Pathway in Colorectal Cancer Cells and Its Phytochemical Analysis.

Han S, Kim H, Lee M, Lee J, Ahn K, Ha I Int J Mol Sci. 2022; 23(23).

PMID: 36499154 PMC: 9740770. DOI: 10.3390/ijms232314826.


Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges.

Chavda V, Patel A, Mistry K, Suthar S, Wu Z, Chen Z Front Oncol. 2022; 12:867655.

PMID: 35425710 PMC: 9004605. DOI: 10.3389/fonc.2022.867655.


References
1.
Wang S, Wu X, Tan M, Gong J, Tan W, Bian B . Fighting fire with fire: poisonous Chinese herbal medicine for cancer therapy. J Ethnopharmacol. 2012; 140(1):33-45. DOI: 10.1016/j.jep.2011.12.041. View

2.
Diehl J, Zindy F, Sherr C . Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997; 11(8):957-72. DOI: 10.1101/gad.11.8.957. View

3.
Sharma J, Al-Omran A, Parvathy S . Role of nitric oxide in inflammatory diseases. Inflammopharmacology. 2008; 15(6):252-9. DOI: 10.1007/s10787-007-0013-x. View

4.
Yan C, Jamaluddin M, Aggarwal B, Myers J, Boyd D . Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther. 2005; 4(2):233-41. View

5.
Kim H, Goo J, Joo Y, Lee H, Lee S, Oh C . Impact on inflammation and recovery of skin barrier by nordihydroguaiaretic Acid as a protease-activated receptor 2 antagonist. Biomol Ther (Seoul). 2013; 20(5):463-9. PMC: 3762283. DOI: 10.4062/biomolther.2012.20.5.463. View